Teladoc Health Target of Unusually High Options Trading (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOC) saw some unusual options trading activity on Thursday. Traders purchased 15,650 call options on the stock. This is an increase of approximately 30% compared to the typical daily volume of 12,026 call options.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on TDOC shares. Bank of America increased their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Canaccord Genuity Group cut their price objective on Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a report on Thursday. Weiss Ratings upgraded shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Finally, Citigroup boosted their price objective on Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a research report on Tuesday, May 5th. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.50.

Trending Headlines about Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter adjusted loss of $0.21 per share, better than the $0.24 consensus estimate. Management also highlighted efficiency efforts, while operating cash flow totaled $64.7 million. Teladoc Health Reports Second Quarter 2026 Results
• Positive Sentiment: Canaccord Genuity lowered its price target from $11 to $10 but retained a “buy” rating, implying substantial potential upside from recent levels. Benzinga analyst price target report
• Positive Sentiment: Unusually heavy call-option activity—15,650 contracts, about 30% above average—suggests some traders are positioning for a rebound, although options flows can be speculative and volatile.
• Neutral Sentiment: The second-quarter net loss was $38.9 million, or $0.21 per share, compared with a $0.19 loss a year earlier. However, first-half cost controls narrowed the net loss even as sales remained under pressure. Do Teladoc’s Weaker Q2 Results Signal a Turning Point in Its Profit Path?
• Negative Sentiment: Revenue fell 4% year over year to $606.9 million, missing estimates of roughly $615.4 million. The company also cited shifting demand for BetterHelp, its mental-health unit, as a major pressure on results. Teladoc tumbles on revenue forecast cut as BetterHelp demand shifts hurt
• Negative Sentiment: Teladoc reduced its full-year 2026 revenue outlook to approximately $2.4 billion, below the $2.5 billion consensus. Third-quarter revenue guidance of $569 million to $609 million also fell well short of the roughly $629 million analyst estimate, while the projected quarterly loss is wider than expected. Why Teladoc Health Stock Is Dropping Following Soft Q3 Outlook

Teladoc Health Stock Down 27.9%

TDOC stock traded down $2.56 during midday trading on Thursday, hitting $6.62. The stock had a trading volume of 17,819,519 shares, compared to its average volume of 5,480,692. The business has a 50-day moving average of $8.21 and a two-hundred day moving average of $6.55. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -6.81 and a beta of 2.10. Teladoc Health has a 52-week low of $4.40 and a 52-week high of $9.89.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.03. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.The business had revenue of $606.93 million during the quarter, compared to analyst estimates of $615.44 million. During the same quarter last year, the firm posted ($0.19) earnings per share. The company’s revenue for the quarter was down 4.0% on a year-over-year basis. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. As a group, equities research analysts forecast that Teladoc Health will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In related news, CEO Charles Divita III sold 19,132 shares of Teladoc Health stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $145,977.16. Following the completion of the transaction, the chief executive officer directly owned 389,894 shares in the company, valued at approximately $2,974,891.22. The trade was a 4.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $60,322.78. Following the sale, the insider directly owned 110,261 shares in the company, valued at $841,291.43. The trade was a 6.69% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 39,195 shares of company stock worth $299,058. 0.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teladoc Health

Hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Teladoc Health by 2.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock valued at $1,542,000 after purchasing an additional 5,235 shares during the last quarter. NewEdge Advisors LLC boosted its position in shares of Teladoc Health by 1,278.7% during the first quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock valued at $90,000 after buying an additional 10,485 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Teladoc Health by 5.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock worth $3,566,000 after buying an additional 24,124 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Teladoc Health in the 1st quarter worth about $615,000. Finally, Envestnet Asset Management Inc. purchased a new position in Teladoc Health in the 2nd quarter worth about $89,000. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.